American Renal Associates Holdings Inc (ARA) Expected to Announce Quarterly Sales of $196.25 Million

Analysts expect American Renal Associates Holdings Inc (NYSE:ARA) to post $196.25 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for American Renal Associates’ earnings, with the highest sales estimate coming in at $196.50 million and the lowest estimate coming in at $196.00 million. American Renal Associates reported sales of $199.11 million in the same quarter last year, which would suggest a negative year over year growth rate of 1.4%. The company is expected to issue its next earnings results on Tuesday, March 6th.

On average, analysts expect that American Renal Associates will report full-year sales of $196.25 million for the current year, with estimates ranging from $747.00 million to $747.20 million. For the next fiscal year, analysts anticipate that the firm will post sales of $822.70 million per share, with estimates ranging from $820.40 million to $825.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for American Renal Associates.

American Renal Associates (NYSE:ARA) last posted its quarterly earnings data on Tuesday, November 14th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.16 by $0.03. The firm had revenue of $187.71 million during the quarter, compared to analyst estimates of $194.60 million. American Renal Associates had a positive return on equity of 15.80% and a negative net margin of 2.15%. American Renal Associates’s revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.28 EPS.

ARA has been the subject of several analyst reports. SunTrust Banks set a $18.00 price objective on American Renal Associates and gave the stock a “buy” rating in a research note on Sunday, October 15th. Zacks Investment Research upgraded American Renal Associates from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Thursday, November 16th. Finally, Leerink Swann restated an “outperform” rating and issued a $17.00 price objective (down from $22.00) on shares of American Renal Associates in a research note on Tuesday, November 21st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. American Renal Associates presently has a consensus rating of “Buy” and a consensus price target of $18.25.

American Renal Associates (ARA) traded down $0.11 during trading hours on Friday, hitting $18.58. The stock had a trading volume of 59,074 shares, compared to its average volume of 155,510. The company has a debt-to-equity ratio of 3.57, a current ratio of 1.16 and a quick ratio of 1.13. The stock has a market cap of $584.54 and a price-to-earnings ratio of -206.44. American Renal Associates has a 52-week low of $9.91 and a 52-week high of $23.30.

A number of institutional investors have recently modified their holdings of the stock. OxFORD Asset Management LLP bought a new position in American Renal Associates in the 3rd quarter worth $290,000. Dimensional Fund Advisors LP boosted its holdings in American Renal Associates by 303.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 50,027 shares of the company’s stock worth $749,000 after buying an additional 37,641 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in American Renal Associates by 67.8% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 65,661 shares of the company’s stock worth $983,000 after buying an additional 26,529 shares during the period. Citadel Advisors LLC bought a new position in American Renal Associates in the 3rd quarter worth $200,000. Finally, Van Berkom & Associates Inc. boosted its holdings in American Renal Associates by 490.5% in the 3rd quarter. Van Berkom & Associates Inc. now owns 2,191,863 shares of the company’s stock worth $32,812,000 after buying an additional 1,820,649 shares during the period. 93.27% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/13/american-renal-associates-holdings-inc-ara-expected-to-announce-quarterly-sales-of-196-25-million-2.html.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply